Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough agrees to wholesale fee-for-service

Executive Summary

Schering-Plough signs fee-for-service drug wholesale agreements with Cardinal, McKesson and AmerisourceBergen. Cardinal and McKesson have set a March 31 deadline for drug manufacturers to agree to distribution contracts following the new compensation model; Pfizer has declared it will not sign a fee-for-service agreement (1"The Pink Sheet" Jan. 24, 2005, p. 8)...

You may also be interested in...



Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal

Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel